140 results about "Biliary tract" patented technology

The utility model relates to a biliary tract woven stent, which comprises a woven stent formed by weaving one or a plurality of woven filaments, the woven filaments are wound along the axis in a positive and negative spiral line mode and interwoven with one another, and the mutually staggered woven filaments form a lap joint buckle structure capable of freely sliding or a hooking buckle structure limited in sliding at nodes. According to the technical scheme, the structure is reasonable, the stent can be degraded automatically while the radial supporting force of the stent is improved, and the stent taking-out operation is omitted.

The invention discloses an application of the number of neutrophils in predicting the curative effect of oncolytic viruses in treating tumors. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the tumor treatment effect, and the applicable tumor syndromes are common, including melanoma, colorectal cancer, esophageal cancer, head and neck tumors, gastric cancer, biliary tract system tumors, sarcoma and other tumors. In the application, the critical value of the number of neutrophils for predicting the tumor treatment effect is 2 * 10 < 9 >-5.5 * 10 < 9 > / L, and the most preferable critical value is 4.0 * 10 < 9 > / L; the curative effect of OH2 single-drug treatment on tumor patients with the neutrophil number level below a critical value is better than that of tumor patients with the neutrophil number level above the critical value.

The invention provides an intraoperative real-time navigation system based on digital twinning, and relates to the technical field of digital twinning, and the system comprises a data collection module which is used for obtaining the three-dimensional form data of a liver and a biliary tract through an intraoperative ultrasonic imaging device, and collecting the elastic modulus distribution parameters of liver parenchyma and a bile duct wall; the construction registration module is used for constructing a real-time digital twin in the liver and gall area based on the three-dimensional form data and the elastic modulus distribution parameters, and carrying out multi-mode non-rigid registration on the digital twin and the liver surface topography and the vascular structure which are subjected to optical coherence tomography in the operation; therefore, a dynamic space mapping relation between the organ structure and the image data is established. According to the method, real-time navigation in the operation is realized through digital twinning, the obstacle avoidance path is updated, and the safety and efficiency in the operation are improved.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention discloses a magnetic control steerable guide wire and an ERCP biliary tract probing and calculus removing operation method thereof.The magnetic control steerable guide wire comprises a magnetic control guide wire body and an external electromagnetic coil, the magnetic control guide wire body comprises a head end magnetic control module, a flexible transition section, a guide wire body section and a near-end control handle, the tail end of the head end magnetic control module is connected with the flexible transition section, and the tail end of the guide wire body section is connected with the external electromagnetic coil; the tail end of the flexible transition section is connected with a guide wire main body section, the tail end of the guide wire main body section is connected with a near-end control handle, and the external electromagnetic coil comprises an annular coil and an insulating layer.By means of guide wire head end magnetic force control and external magnetic field guiding, the problem that guide wire intubation is difficult due to the fact that a gallbladder duct and a total hepatic duct form an angle is solved; and through magnetic control of the head end of the guide wire and guidance of an external magnetic field, the problem that the guide wire is difficult to intubate due to angulation of the gallbladder duct and the total hepatic duct is solved, and the success rate and the safety of taking out the biliary calculus are improved.

The utility model discloses a multifunctional biliary tract internal and external drainage tube combination device applied to a patient suffering from hilum cholangiocarcinoma. A drainage catheter is transited from a shaping area and an elastic cabin area to an internal drainage area to form a cylindrical cone; side holes are formed in the inner drainage area and the shaping area; a marker point is arranged between the inner drainage area and the missile cabin area, the missile cabin area is distributed between the inner drainage area and the shaping area, a one-way valve is arranged at the contact position between the shaping area and the missile cabin area, a hole channel is formed in the outer wall, extending into the marker point from the missile cabin area along the one-way valve, of the missile cabin area, and the hole channel forms a missile cabin in the missile cabin area. The magazine is used for placing radioactive particles; the hard support is used in cooperation with the drainage catheter, the hard support penetrates into the outer drainage area and then is pulled to the end of the inner drainage area, and the curled part of the shaping area of the hard support is straightened. The utility model can realize internal and external drainage and achieve the purpose of local tumor treatment, and is simple and convenient to operate and easy for medical staff to use.

The invention discloses a biliary tract drainage tube with a particle carrying radiotherapy function. The biliary tract drainage tube comprises a tube body, a stay wire and a stay wire traction fastening device, a bendable pigtail section is arranged at the front end of the tube body, a drainage cavity and a particle cavity are axially arranged in the tube body, and drainage holes communicated with the outside and the drainage cavity are formed in the tube wall of the pigtail section. The stay wire extends to the pigtail section along the drainage cavity and passes through stay wire holes at the head and tail of the pigtail section, and two ends of the stay wire extend out of the rear end of the tube body and converge to the fastening device. The front end of a first connector sleeve of the fastening device is fixedly connected with the rear end of the tube body and communicated with the drainage cavity through a connector inner tube, and a second connector sleeve loosely sleeves the connector inner tube. One end of the pull wire is fixed to the first connector sleeve, the other end of the pull wire movably penetrates out of the second connector sleeve, the pigtail section can be bent by pulling the pull wire, the second connector sleeve is rotated to a set angle, the pull wire is clamped through angle dislocation, and the pigtail section is kept in the bent state. Bending of the pigtail section can be conveniently controlled, the anchoring state can be stably maintained, and the safety and reliability of clinical catheterization can be effectively improved.

The present invention relates to a method for treating cancer in a human subject. The method comprises: (a) orally administering enuracil to the subject at a dose of 30-60 mg / day; (b) orally administering capecitabine to the subject for consecutive 2-14 days at a dose of about 140-700 mg / day or a dose that provides a 5-FU exposure (AUC) of about 1500 h * ng / mL or greater at least 10 hours after step (a); and (c) repeating the steps (a) and (b) 3-14 days after the step (b). The pharmaceutical composition is suitable for treating colorectal cancer, gastrointestinal tumor, breast cancer, pancreatic cancer, head and neck cancer, lung cancer or advanced biliary tract cancer.

The present invention relates to an equipment for magnetic recanalization of benign biliary strictures. The equipment (100) includes a wire-guided magnet pusher tube (102a), atleast one magnet (110), and a magnet retrieval tube (102b). The equipment (100) works in conjunction with a visualization system to guide placement of the magnet (110) at the target site for recanalization of the biliary stricture. The magnet (110), may be deployed at opposing ends of a biliary stricture to create a controlled recanalization channel via magnetic attraction. The deployment process can be performed using endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage (PTBD), or a combination of both. Magnets may be retrieved following recanalization using biopsy forceps or allowed to pass naturally through the digestive tract, avoiding permanent implantation.

The utility model discloses a biliary tract inside and outside drainage device which comprises a drainage catheter, a fixing stay wire and a hard sleeve. The drainage catheter is composed of an inner drainage area, a narrow section covering area, a shaping area and an outer drainage area, and the interior of the drainage catheter is of a hollow structure. One end of the inner drainage area is designed into a cylindrical cone; a clamping table is arranged at one end of the outer drainage area and used for connecting a cap or a drainage bag; side holes penetrating through the inner cavity are formed in the outer walls of the inner drainage area and the shaping area; a marker point is arranged between the rear end of the side hole of the inner drainage area and the narrow section coverage area; the shaping area is curled into a loop in a natural state, and the shaping area can be straightened through the hard sleeve; the narrow section coverage area is distributed between the inner drainage area and the shaping area; the fixing stay wire comprises a fixing piece and a stay wire, and the tail end of the stay wire is connected with the fixing piece. The drainage catheter main body adopted by the utility model is made of a material with good biocompatibility; and internal drainage and external drainage can be realized. Multiple side holes are formed in the middle and the head end of the drainage tube, sufficient drainage is promoted, and infection risks are reduced.

The invention discloses an application of an OH2 oncolytic virus combined with a PD-1 inhibitor in preparation of an antitumor drug. The OH2 oncolytic virus and the PD-1 inhibitor are jointly applied to tumor treatment, and through the synergistic effect of the OH2 oncolytic virus and the PD-1 inhibitor, the anti-tumor immune response is enhanced, and the treatment effect is improved. According to the combined treatment scheme, tumor cells can be directly killed, recurrence and metastasis of tumors can be inhibited by activating systemic immune response, and a new treatment choice is provided for tumor patients. In the application, the neutrophile granulocyte number level in the blood of a tumor patient is closely associated with the treatment effect of the anti-tumor medicine, the anti-tumor medicine can be used for evaluating the treatment effect, and the anti-tumor medicine is suitable for common tumor adaptations including colorectal cancer, esophageal cancer, head and neck tumor, gastric cancer, biliary tract system tumor, sarcoma, melanoma and other tumors.

The invention relates to the technical field of medical instruments, and discloses a visual biliary tract rotary cutting biopsy expansion system assembly which comprises a conical sleeve, a visual mechanism is fixedly connected to the interior of the conical sleeve, a holding mechanism is installed on the left side of the visual mechanism, a rotary cutting mechanism is installed at the left end of the holding mechanism, and the visual mechanism comprises a cable. The exterior of the cable is fixedly connected to the interior of the conical sleeve, the top end of the cable is fixedly connected with a golden finger, the left end of the conical sleeve is fixedly connected with a protection assembly, the left end of the protection assembly is fixedly connected with a Luer lock cap, and the interior of the protection assembly is fixedly connected with an insertion pipe; a light source is fixedly connected into the protection assembly. The inside of the biliary tract is uniformly and sufficiently illuminated through the light source, a clear observation view is provided for a doctor, the doctor can accurately judge the illness state, and the situation that the positive rate of hepatopathic bile duct malignant stenosis biopsy is not high is reduced.

The invention provides a kit or device for detecting biliary tract cancer, and a detection method. The present invention relates to: a kit or device for detecting biliary tract cancer, which contains a nucleic acid capable of specifically binding to miRNA in a specimen of a subject; and a method for detecting biliary tract cancer, which includes measuring the miRNA in vitro.

The present application relates to the field of medical immunology technology, and more particularly to biomarkers and their application in the assessment of liver damage in end-stage liver disease. In the present application, the proportion of CCR7+CD8+ T cells in CD8+ T cells is used as a marker for the assessment of liver damage in end-stage liver disease, which can reflect the liver immune status of end-stage liver disease, especially the assessment of the degree of liver damage, has high specificity and sensitivity, and provides a scientific basis for the development of clinical individualized treatment plan, and has good practical application value. At the same time, while reflecting the liver damage process of the patient, it can also reflect the immune status of the patient's liver, and can provide certain theoretical basis for slowing down the disease progression of subsequent biliary atresia and other end-stage liver disease patients with liver damage.

The utility model discloses a kind of anti-coming-off pipe device for clinical biliary tract drainage tube, it is related to medical instrument field, specifically for a kind of anti-coming-off pipe device for clinical biliary tract drainage tube, including the fixing plate for fixing biliary tract drainage tube, the both sides of the fixing plate are respectively equipped with adjusting groove, the fixing plate is equipped with the positioning column of adjusting groove insertion, the tail end of the positioning column is equipped with positioning plate, the sliding slot that is equipped with with positioning plate cooperation on fixing plate, the side of the fixing plate is equipped with the buckle plate that is with positioning column cooperation, two described buckle plate between are equipped with the pull rope for fixing biliary tract drainage tube joint, the utility model solves the biliary tract drainage tube of current clinical use, it is easy to influence the normal flow guide of biliary tract drainage tube, but because pipeline is long also easy to sway, it is easy to scratch patient skin, there is another common way is just with a rope to bind the interface of the other end of drainage tube, but the tightness of biliary tract drainage tube cannot be adjusted using this way.

The present application relates to the technical field of biotechnology, more particularly to a biomarker for distinguishing benign biliary disease and cholangiocarcinoma and application thereof. The biomarker for distinguishing benign biliary disease and cholangiocarcinoma provided by the present application comprises 20 kinds of lipids and / or 5 kinds of polypeptides, and the single lipid group or single polypeptide group is used as a biomarker to distinguish benign biliary disease and cholangiocarcinoma, which has high sensitivity. When the lipid group and the polypeptide group are used as multi-group biomarkers, the sensitivity and accuracy of the discrimination can be further improved. In addition, the biomarker combination provided by the present application exists in serum, which is more suitable for non-invasive collection. The reagent or kit prepared based on the biomarker combination is more convenient for popularization and use. The risk prediction model for benign biliary disease and cholangiocarcinoma constructed based on the above biomarker has higher accuracy compared with the existing CA19-9 marker method, whether it is a single omics model or a double omics model.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject.

The invention discloses a prognostic scoring method and system for predicting advanced biliary tract malignant tumor immunotherapy, and belongs to the technical field of advanced biliary tract malignant tumor immunotherapy. The method comprises the following steps: firstly, generating random replacement copies for real variables to obtain shadow variables, and classifying the real variables into related classes by comparing importance scores of the random replacement copies and the shadow variables; real variables in related classes are screened based on LASSO regression coefficients, and a variable set is formed; combining the variables in the set, and screening out a variable combination corresponding to a minimum AIC value model according to an AIC criterion to obtain a prognosis key variable set; calculating an index score according to the COX regression coefficient of each real variable; and finally, adding the index scores of the variables in the prognosis key variable set of each patient to obtain a prognosis BICCAPS score. Through three-step progressive screening of the random forest algorithm, the LASSO and the optimal subset method, the problems of variable screening, colinearity and model conciseness in high-dimensional clinical data modeling are solved.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The present disclosure pertains to the field of biomedicines and relates to use of an anti-HER2 antibody-drug conjugate in the treatment of biliary tract cancer. The present disclosure also relates to use of an anti-HER2 antibody-drug conjugate in the preparation of a medicament for treating biliary tract cancer in a subject. The present disclosure also relates to a method for treating biliary tract cancer in a subject, the method comprising administering an anti-HER2 antibody-drug conjugate to the subject. The method provides benefits for subjects with biliary tract cancer and has good safety.

The utility model discloses a superfine soft choledochoscope guiding aspirator under a laparoscope, which is specially designed for a common bile duct exploration operation through a gallbladder tube superfine choledochoscope and comprises a guiding tube capable of being bent by 150 degrees, the inner diameter of the guiding tube is 3.0 mm, and the superfine choledochoscope can pass through the guiding tube; the guide tube is provided with a small hole and an aspirator interface to attract normal saline flowing out of the choledochoscope to keep the surgical field clear; the head of the guide tube is provided with a soft cap to prevent air leakage. By means of flexible bending design, accurate size control and efficient suction function, accuracy and safety of an operation are remarkably improved. Meanwhile, the choledochoscope guiding device is simple in structure and convenient to operate, and the problems existing in a traditional choledochoscope guiding device are effectively solved. The guide aspirator is suitable for laparoscopic common bile duct exploration operation, has wide clinical application prospects and market value, and provides a new solution for treatment of biliary tract diseases.

The utility model discloses a pusher for a partially-covered or fully-covered biliary tract metal stent. The pusher comprises a pusher operating handle, the outer sheath tube is connected with the pusher operating handle, and the inner part of the outer sheath tube is hollow to form a channel; a conical head part is arranged at one end, far away from the pusher operating handle, of the outer sheath tube, the pusher operating handle is connected with an inner tube, and one end, far away from the pusher operating handle, of the inner tube is connected with the conical head part; the driving end of the pusher operating handle drives the inner tube to move in the axial direction of the outer sheath tube so as to drive the conical head part at the front end to move; a metal stent is arranged on the outer ring of the inner tube, and the metal stent is a partially-covered biliary tract metal stent or a fully-covered biliary tract metal stent; the driving end of the pusher operating handle drives the inner tube to move in the axial direction of the outer sheath tube so as to drive the metal support to move towards the outside or the inside of the outer sheath tube. According to the pusher, the operation process is simplified, the operation time is shortened, the operation success rate is improved, and complications are reduced.

The application discloses a medical knowledge enhanced question answering and auxiliary diagnosis and treatment method for biliary surgery, comprising the following steps: recognizing biliary surgery corpus through an entity recognition model to obtain a plurality of biliary surgery entities and extracting the causal relationship between the biliary surgery entities; constructing a biliary surgery knowledge graph based on the biliary surgery entities and the causal relationship, summarizing the information in each biliary community to obtain a plurality of community abstracts; segmenting the community abstracts to obtain a plurality of abstract blocks, calculating the scores of the abstract blocks, screening the abstract blocks according to the scores, obtaining high-relevance abstract blocks, inputting the query text of a user, a structured generation template of a causal chain and the high-relevance abstract blocks into a large language model to obtain a clinical answer text. The application accurately matches clinical causal information through a causal perception mechanism, and outputs answers conforming to a clinical thinking process based on the structured generation of a causal chain, thereby improving the accuracy and interpretability of diagnosis and treatment assistance.

The present invention provides a bifunctional molecular compound that induces MMP-7 protein degradation or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein the structure of the compound is shown in Formula I or II: #imgabs0#Formula I; #imgabs1#Formula II. The present invention also provides a method for preparing the above-mentioned compound and a pharmaceutical composition. In addition, the present invention also provides the use of the above-mentioned compound, its pharmaceutically acceptable salt, hydrate, prodrug, or pharmaceutical composition in the preparation of a drug for treating biliary atresia. The present invention is supported by PROTAC technology and uses MMP-7 inhibitors as raw materials to synthesize bifunctional molecular compounds with different linker lengths that induce MMP-7 protein degradation; by using the bifunctional molecular compound after biliary atresia surgery, effective degradation of MMP-7 protein can be achieved, inflammatory bile duct damage and liver fibrosis progression can be inhibited, and a new treatment strategy for biliary atresia can be provided.

The present invention discloses a degradable stent suitable for end-to-end anastomosis of bile ducts during liver transplantation, comprising a transverse stent assembly, a longitudinal stent assembly and a periodically degradable connecting assembly, a transverse tube body, a retaining net, a connecting sleeve, an end sleeve, an air-avoiding hole, a longitudinal tube body, a periodically degradable sleeve, and a periodically degradable filling block. Firstly, the transverse stent can achieve docking of donor bile ducts and recipient bile ducts of different diameters, thereby improving matching and applicability. The longitudinal stent can facilitate in vitro communication in the early stage of catheterization, thereby facilitating drainage and perfusion. Secondly, the periodically degradable sleeve and the periodically degradable filling block can be continuously degraded by the patient's body secretions and decompose after a certain period of time, thereby eliminating the docking between the transverse stent assembly and the longitudinal stent assembly, separating them, and facilitating the disassembly and removal of the longitudinal stent assembly. Finally, the grid structure of the retaining net can facilitate the accumulation of bioadhesives, thereby achieving the blocking of the retaining net. After the longitudinal stent assembly is separated from the transverse stent assembly, the transverse tube body in the transverse stent assembly is in a sealed state.

A delivery endcap assembly is adapted for use with a biliary access device and is adapted to permit a medical device to be delivered through the biliary access device. The delivery endcap assembly includes a securement portion adapted to be releasably securable to a proximal end of the handle after the one or more removable components have been removed from the handle, a tapered portion extending proximally from the securement portion, a rotation hub adapted to be coupled to the securement portion, a valve adapted to be coupled to the rotation hub and a lumen extending through the delivery endcap assembly, wherein the lumen extending through the delivery endcap assembly is adapted to permit a medical device within an introducer sheath to be advanced through the biliary access device.

The invention belongs to the technical field of biological medicines, and particularly relates to application of PF-06260933 in preparation of a medicine for treating biliary atresia. The invention provides an application of an HGK inhibitor PF-06260933 in preparation of a medicine for treating biliary atresia. A BA organ and biliary duct ligation (BDL) induced mouse model is constructed, PF-06260933 is adopted to inhibit pro-inflammatory and pro-fibrosis related signal channels of biliary duct epithelial cells, and the improvement effect of PF-06260933 on biliary duct atresia pathological phenotypes is observed. Results show that the PF-06260933 treatment not only can significantly improve inflammatory fibrosis phenotypes of BA organs, but also can significantly improve mouse liver functions, relieve liver inflammation and fibrosis, and effectively reverse pathogenic activation phenotypes of bile duct epithelial cells. Compared with the traditional niberous surgery or non-specific immunosuppression therapy, the method has the advantages of remarkable progress and huge clinical application potential.

The transparent cap of the choledochoscope comprises a cap portion and a connecting portion, the tube wall of the front end, away from the connecting portion, of the cap portion is in an arc shape, and a first annular thread is arranged on the inner wall of the connecting portion. The choledochoscope tip is of a convex structure composed of a head part and a body part, the outer diameter of the head part is smaller than that of the body part, a second annular thread is arranged on the outer wall of the head part, and the second annular thread is connected with the first annular thread in a matched mode to achieve connection between the connecting part and the head part; and the outer diameter of the connecting part is the same as that of the body part. The transparent sleeve can be installed at the front end of a choledochoscope to carry out operations such as gall bladder or bile duct washing, calculus removal, stenosis expansion, gall bladder duct or Oddi sphincter exploration and the like; the transparent cap is firmly mounted and cannot fall off; the outer diameter of the connecting part of the transparent cap is consistent with the outer diameter of the choledochoscope body part, the tube wall at the front end of the cap part of the transparent cap is arc-shaped, and tissues such as fistulous tracts, gallbladders and bile duct mucosa are not damaged in the choledochoscope examination and treatment process.

The utility model provides a choledochoscope calculus removing net basket which comprises a metal net basket, an outer sheath tube and a handle, and the outer sheath tube is connected with the handle. The metal mesh basket comprises four mesh basket wires and a connecting rod, the head ends of the four mesh basket wires are fixedly connected together and are in an inverted omega shape, and the head end of the connecting rod is fixedly connected with the tail ends of the four mesh basket wires; the outer sheath tube comprises a drainage tube section I, a drainage tube section II and a drainage tube section III, and the head end of the metal net basket is contained in the drainage tube section I; the drainage tube section II is a four-channel tube, four channels I are formed in the drainage tube section II, and a mesh basket wire is accommodated in each channel I; the connecting rod is arranged in the drainage tube section III; the lower end of one side of the handle is biconcave, the upper end of the other side of the handle is provided with a push rod moving button, and a push rod is arranged in the handle and connected with the connecting rod and the push rod moving button. The calculi in the gall bladder or the bile duct can be extracted through the choledochoscope, the mesh basket wires form the spherical mesh basket from small to large when being led out through the four channels, the spherical mesh basket is stable in shape, and the calculi of different sizes can be extracted conveniently.